Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Jun 06, 2018 2:13am
205 Views
Post# 28130320

RE:RE:Taimed agm

RE:RE:Taimed agm
SPCEO1 wrote:
Dwizell wrote: Looks like the assembly is doing bad .... Taimed down under 300twd


Well over T$300 now and hardly off at all for the day. A taiwanese investor ahs claimed that the CEO said the biggesst challenge for the company is supply because it is selling so well. Of course, that too could be fake news since I really don't think demand s so fantastic that supply is an issue.


WRT supply, Wuxi has pretty large production capacity that cant be what he's talking about. If he's referring to the pre-existing manufactured material that might make more sense in terms of limited supply. Lead times on getting biologics manufactured by CMO's depends on how full their calender is but is generally measured in months, the process itself for a batch, from start culture to finished vial, is going to be a month or more.

Guessimate on the pre-existing supply

3 batches of 2000l cultures is what taimed's presentation suggests.

2g of monoclonal antibody per litre would be a reasonable yield. (1g-5g are reasonable yields)

That gives you 12,000g of drug
1vial =  0.2g
So 12,000g would give you 60,000 vials.

1 patient uses 110 vials in their first year.
So 60,000 vials would be good for 550 patients.

If those numbers are right (or even double that) then it would be reasonable to start planning for new batches to be manufacted now I think. Not that they are going to run out of supplies any time soon but to feel certain about supplies into the next year or so.

Bullboard Posts